-
Ultimovacs Announces Completed Patient Recruitment in NIPU Phase II Clinical Trial of UV1 in Mesothelioma
-
Cemiplimab to replace pembrolizumab in UV1 Phase II LUNGVAC Trial
-
Ultimovacs Announces Completed Patient Recruitment in TENDU Phase I Clinical Trial in Prostate Cancer
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs ASA: Mandatory notification of trade by primary insider
-
Ultimovacs ASA Reports Third Quarter 2022 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to Third quarter 2022 results webcast presentation
-
Ultimovacs Announces First Patient Randomized in Phase II LUNGVAC Trial of UV1 in Non-Small Cell Lung Cancer (NSCLC)
